CRIS Current Research Information System

MAZZELLA, GIUSEPPE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 12.369
AS - Asia 10.619
EU - Europa 7.509
AF - Africa 606
SA - Sud America 516
Continente sconosciuto - Info sul continente non disponibili 462
OC - Oceania 18
Totale 32.099
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 12.179
VN - Vietnam 3.695
SG - Singapore 2.700
CN - Cina 2.202
GB - Regno Unito 1.987
IT - Italia 1.102
DE - Germania 958
SE - Svezia 838
HK - Hong Kong 575
FR - Francia 535
IN - India 489
RU - Federazione Russa 436
UA - Ucraina 408
BR - Brasile 356
IE - Irlanda 304
NL - Olanda 251
ZA - Sudafrica 191
BD - Bangladesh 185
JP - Giappone 184
EE - Estonia 158
CI - Costa d'Avorio 155
KR - Corea 135
CH - Svizzera 108
CA - Canada 106
FI - Finlandia 101
TG - Togo 89
BG - Bulgaria 67
PH - Filippine 61
SC - Seychelles 61
AR - Argentina 57
TH - Thailandia 49
JO - Giordania 48
PL - Polonia 47
ID - Indonesia 41
NG - Nigeria 40
GR - Grecia 38
BE - Belgio 36
AT - Austria 35
EC - Ecuador 35
TW - Taiwan 35
TR - Turchia 34
MX - Messico 33
IQ - Iraq 31
PK - Pakistan 31
ES - Italia 27
IR - Iran 22
SA - Arabia Saudita 21
EG - Egitto 16
AU - Australia 14
JM - Giamaica 14
LB - Libano 14
CO - Colombia 13
PE - Perù 13
UZ - Uzbekistan 12
CL - Cile 11
LT - Lituania 11
MY - Malesia 11
VE - Venezuela 10
CZ - Repubblica Ceca 9
ET - Etiopia 9
NI - Nicaragua 9
PY - Paraguay 9
IL - Israele 8
KE - Kenya 8
MA - Marocco 8
DZ - Algeria 7
RO - Romania 7
TN - Tunisia 7
DK - Danimarca 6
PT - Portogallo 6
SI - Slovenia 6
BO - Bolivia 5
CR - Costa Rica 5
HR - Croazia 5
MK - Macedonia 5
SY - Repubblica araba siriana 5
UY - Uruguay 5
AO - Angola 4
KW - Kuwait 4
MD - Moldavia 4
NO - Norvegia 4
NZ - Nuova Zelanda 4
PS - Palestinian Territory 4
BB - Barbados 3
BH - Bahrain 3
HN - Honduras 3
LK - Sri Lanka 3
MM - Myanmar 3
NP - Nepal 3
SV - El Salvador 3
AE - Emirati Arabi Uniti 2
AL - Albania 2
AZ - Azerbaigian 2
BF - Burkina Faso 2
DO - Repubblica Dominicana 2
EU - Europa 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LY - Libia 2
Totale 31.609
Salva come PNG Salva come JPEG
Città #
Singapore 1.885
Southend 1.784
Fairfield 1.338
Ashburn 1.217
Chandler 846
Ho Chi Minh City 827
Hanoi 738
San Jose 609
Hong Kong 542
Wilmington 512
Santa Clara 507
Woodbridge 499
Houston 480
Seattle 470
Dong Ket 439
Princeton 383
Cambridge 366
Dublin 302
Ann Arbor 298
Boardman 284
Beijing 273
Council Bluffs 268
Jacksonville 242
Bologna 232
Hefei 207
Lauterbourg 187
Nanjing 179
Westminster 175
New York 171
Los Angeles 164
Abidjan 155
Tokyo 153
Padova 149
Dallas 120
Da Nang 119
Saint Petersburg 113
Berlin 110
Buffalo 109
Haiphong 108
Milan 91
Lomé 89
Medford 86
Seoul 85
Bern 78
Helsinki 77
Shenyang 75
Frankfurt am Main 74
Jinan 73
Dearborn 65
Hebei 64
San Diego 61
Sofia 61
São Paulo 61
Changsha 58
Biên Hòa 56
Nanchang 55
Munich 52
Shanghai 51
Hải Dương 49
Amman 48
Thái Nguyên 48
Guangzhou 47
Bremen 45
Ha Long 45
Quận Bình Thạnh 44
Redondo Beach 43
Can Tho 42
Florence 41
Mülheim 41
Abeokuta 39
Tianjin 38
Des Moines 37
Chicago 35
Phoenix 35
Turin 35
Bắc Ninh 33
Brussels 31
Johannesburg 31
London 31
Zhengzhou 31
Falkenstein 29
Hangzhou 29
Mahé 29
Jiaxing 28
Toronto 28
Redwood City 27
Ninh Bình 26
Falls Church 25
Pune 25
Redmond 25
Wuhan 24
Amsterdam 23
Bắc Giang 23
Orem 23
San Francisco 23
Vinh 23
Xi'an 23
Yubileyny 23
Rome 22
Shenzhen 22
Totale 20.241
Salva come PNG Salva come JPEG
Nome #
G-CSF in Peg-IFN induced neutropenia in liver transplanted patients with HCV recurrence 617
G-CSF administration is not related to PEG-IFN alfa-213 treatment duration nor response in liver transplanted patients with HCV recurrence 522
Antiinflammatory Effect of Phytosterols in Experimental Murine Colitis Model: Prevention, Induction, Remission Study 509
Outcomes and survival after TIPS positioning: a single center experience 409
Two cases of severe autoimmune manifestations following virological response to peginterferon alpha- 2b + ribavirin in liver transplanted patients with recurrence of chronic hepatitis C 343
Clinical trial: peg-interferon alfa-2b and ribavirin for the treatment of genotype-1 hepatitis C recurrence after liver transplantation 333
A new model for portal protein profile analysis in course of ileal intraluminal bile acid infusion using an in situ perfused rat intestine. 305
Adefovir and lamivudine combination therapy is superior to ADV monotherapy for lamivudine-resistant patients with HBeAG-negative chronic hepatitis B 304
A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis 278
Curcuma longa Extract Exerts a Myorelaxant Effect on the Ileum and Colon in a Mouse Experimental Colitis Model, Independent of the Anti-Inflammatory Effect 259
Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid. 258
Relationship between indocyanine green retention test, decompensation and survival in patients with Child-Pugh A cirrhosis and portal hypertension 256
Berberine and its metabolites: Relationship between physicochemical properties and plasma levels after administration to human subjects 248
G-CSF administration is not related to Peg-IFN alfa-2b treatment duration nor response in liver transplanted patients with HCV recurrence. 246
A RETROSPECTIVE STUDY ON INTRAHEPATIC CHOLESTASIS OF PREGNANCY: MARKERS OF PREMATURE DELIVERY 239
Utility of Doppler-Ultrasound and Liver Elastography in the Evaluation of Patients with Suspected Pregnancy-Related Liver Disease 238
AISF position paper on liver disease and pregnancy 230
Curcuma longa L. as a therapeutic agent in intestinal motility disorders. 2: Safety profile in mouse. 229
The future of dual therapy for hepatitis C virus 225
Complete Remission of Advanced Hepatocellular Carcinoma Treated with Sorafenib and Concomitant Appearance of IgG4- related Diseases. A Case Report 224
Correlazione materno-fetale degli acidi biliari in corso di colestasi gravidica 222
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation. 222
Adverse effects of proton pump inhibitors. 221
Size and location of spontaneous portosystemic shunts predict the risk of decompensation in cirrhotic patients 221
High Doses of Ursodeoxycholic Acid Up-Regulate the Expression of Placental Breast Cancer Resistance Protein in Patients Affected by Intrahepatic Cholestasis of Pregnancy 220
Hepatocellular carcinoma risk assessment by the measurement of liver stiffness variations in HCV cirrhotics treated with direct acting antivirals 219
Higher doses of peginterferon alpha-2b administered twice weekly improve sustained virological response in difficult-to-treat patients with chronic hepatitis C: results of a pilot randomized study 218
Immune inflammation indicators and ALBI score to predict liver cancer in HCV-patients treated with direct-acting antivirals 218
Clinical efficacy and effectiveness of ursodeoxycholic acid in cholestatic liver diseases. 216
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 215
Generation of a novel antibody probe to the Apical Sodium-Dependent Bile Acid Transporter that inhibits ileal bile acid absorption 213
Economic Consequences of Investing in Anti-HCV Antiviral Treatment from the Italian NHS Perspective: A Real-World-Based Analysis of PITER Data 209
Interleukin 28 polymorphisms and hepatocellular carcinoma development after direct acting antiviral therapy for chronihepatitis c 209
Direct acting antivirals for the treatment of elderly patients with HCV advanced disease in the real life practice 208
Long term follow-up and outcome of liver transplantation for alcoholic liver disease: a single center case-control study 207
Treatment with direct acting antiviral agents-based regimen in HCV patients with advanced liver disease: Analysis of an Italian multicenter observational study 206
Alisporivir for the treatment of chronic HCV 205
Measurement of spleen stiffness to evaluate portal hypertension and the presence of esophageal varices in patients with HCV-related cirrhosis 204
Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. 203
Imbalance of Neutrophils and Lymphocyte Counts Can Be Predictive of Hepatocellular Carcinoma Occurrence in Hepatitis C-related Cirrhosis Treated With Direct-acting Antivirals 203
The impact of assisted reproductive technology and chorionicity in twin pregnancies complicated by obstetric cholestasis 200
Imaging features of microvascular invasion in hepatocellular carcinoma developed after direct-acting antiviral therapy in HCV-related cirrhosis 197
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 196
Severe immune thrombocytopenia after peg-interferonalpha2a, ribavirin and telaprevir treatment completion: A case report and systematic review of literature 195
Ribavirin for chronic hepatitis C: And the mystery goes on. 193
Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: Predictive role in HCC development in cirrhotic patients 187
IL28 polymorphism and HCC after DAAs for chronic hepatitis C 185
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 184
Systemic fungemia and hepatic localizations of Fusarium solani in a liver transplanted patient: An emerging fungal agent. 183
HIGH FREE AND GLYCOCONJUGATED AND LOW TAUROCONJUGATED BA LEVELS IN SERUM ARE THE MIRROR OF INTESTINAL EVENTS AND HEPATIC UPTAKE 181
High incidence of allograft dysfunction in liver transplant patients treated with PEG-Interferon alfa-2b and Ribavirin for hepatitis C recurrence: possible de novo autoimmune hepatitis? 180
Spleen stiffness measurement: A useful prognostic tool in HCV patients treated with DAAs regimens 180
Small (≤3cm) Hepatocellular Carcinoma in Cirrhosis: the Role of Double Contrast Agents MR Imaging vs. Multi-Detector Row CT 179
Colonic gallstone ileus treated with radiologically guided xtracorporeal shock wave lithotripsy followed by endoscopic extraction. 177
Spleen stiffness decrease as mirror of portal hypertension changes after successful interferon-free therapy in chronic-HCV patients 177
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 177
Efficacy of ursodeoxycholic acid administration on clinical manifestations of gallstones and gastrointestinal motility 176
Ductal stones recurrence after extracorporeal shock wave lithotripsy for difficult common bile duct stones: Predictive factors 176
THU-492 - Liver stiffness and serum fibrosis biomarker variations after DAAs treatment: predictive role in hepatocellular carcinoma development in in cirrhotic patients 176
Pharmacological modulation of MRP2 in primary biliary cirrhosis 175
Spleen stiffness mirrors changes in portal hypertension after successful interferon-free therapy in chronic-hepatitis C virus patients 175
Terapia cellulare in Epatologia 174
THU-490 - Spleen stiffness measurement: a useful prognostic tool in HCV patients treated with DAAs regimens 174
Correlation between Indocyanine green retention test and esophageal varices among patients with hepatocellular carcinoma 172
Spleen stiffness measurement can predict clinical complications in compensated HCV-related cirrhosis: a prospective study 168
Orthotopic liver transplantation (OLT): contribution of imaging and interventional radiology in preparing the transplantation and managing complications. Part 2: post-OLT complications and their treatment. 167
Regolazione dei trasportatori placentari degli acidi biliari MRP2, MRP3, MRP4 da parte dell’acido ursodesossicolico in corso di colestasi gravidica 167
Indocyanine Green 15-min Retention test (ICG-r15) as a predictor of clinical decompensation in patients with compensated liver cirrhosis. 167
Superior efficacy of twice a week administration of peginterferon alpha-2b plus ribavirin in obtaining SVR in HCV genotype 1 166
Chronic NSAIDs Therapy and Upper Gastrointestinal Tract – Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management 166
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 166
Proton pump inhibitors in cirrhosis: tradition or evidence based practice? 166
A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices 166
A Placebo-controlled trial of obeticholic acid in primary biliary cholangitis 165
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial 165
Fatty liver in pregnancy: a narrative review of two distinct conditions 165
Spleen Stiffness Measurements Predict the Risk of Hepatic Decompensation after Direct-Acting Antivirals in HCV Cirrhotic Patients 165
CMV infection and biliary tract complications are related with a poor outcome of liver transplantation for HCV-related cirrhosis 164
Incidence of gallstone disease in Italy: Results from a multicenter, population-based Italian study (the MICOL project). 164
Persistent Fever and Abdominal Pain in a Young Woman With Budd-Chiari Syndrome 163
Indocyanine green clearance (ICG) as a predictor of 2-years clinical decompensation and mortality in patients with compensated liver cirrhosis 163
Indocyanine Green Clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis 163
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update 160
Mathematical model predicting high hepatocyte proliferation index and risk of HCC in patients with HCV related cirrhosis: a proposal for clinical validation 159
Orthotopic liver transplantation (OLT): contribution of diagnostic imaging and interventional radiology in preparing the transplantation and managing complications. Part 1: Indications, surgical technique, diagnostic imaging and interventional radiology before transplantation from cadaveric and living donor. 158
An unusual cause of weight loss in a young Caucasian man 158
Indocyanine green clearance (ICG) as a predictor of clinical decompensation and mortality in patients with compensated liver cirrhosis. 158
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 158
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease. 157
Indocyanine green as a predictor of clinically significant portal hypertension in a prospective cohort study of patients with chronic liver disease 157
The foetal-maternal circulation of bile acids and bilirubin: effects of cholestasis and UDCA administration. 156
MRP2 is upregulated by UDCA in cholestasis of pregnancy. 156
Chemiluminescence measurement of autotaxin activity in human serum 155
Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial 155
Noninvasive diagnosis of portal hypertension and esophageal varices through the identification of liver blood flow markers 155
P.09.6 IL28 POLYMORPHISM AND HCC DEVELOPMENT AFTER DAAS FOR CHRONIC HEPATITIS C 154
Breath tests with stable isotopes: have they a role in liver transplantation? 151
Effects of UDCA on the foetus-maternal circulation of bilirubin in cholestasis of pregnancy 151
Imaging Features of Microvascular Invasion in Hepatocellular Carcinoma Developed in HCV-Related Cirrhosis after Direct-Acting Antiviral Therapy. 151
Management of hepatic encephalopathy: focus on antibiotic therapy 151
Totale 20.676
Salva come PNG Salva come JPEG
Categoria #
all - tutte 86.216
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 86.216
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.432 0 146 203 232 329 195 88 200 138 170 1.164 567
2022/20233.455 417 484 198 466 231 268 90 174 605 85 235 202
2023/2024994 70 161 58 120 82 238 37 52 69 60 21 26
2024/20253.822 150 673 349 239 674 178 214 96 43 329 146 731
2025/202610.725 1.986 753 779 562 1.040 533 921 384 2.055 734 630 348
2026/2027505 198 307 0 0 0 0 0 0 0 0 0 0
Totale 32.099